Poseida Therapeutics competitors

J Scott Wolchko are a President/CEO/COO at FATE THERAPEUTICS INC and Board Member at FATE THERAPEUTICS INC. They have worked as Chief Financial Officer at Bocada and VP:Operations/CFO at FATE THERAPEUTICS INC. J studied at University of Virginia and Alpha Omega Alpha Medical Honor Society.

Mr. Onsi has served as our Chief Financial Officer, Treasurer and Secretary since our inception in 2011. Mr. Onsi has been at HealthCare Ventures since 2007, including serving as a managing director since 2009 and the chief executive officer of Tensha Therapeutics, Inc. which was sold to Roche Holdings, Inc. in 2016. Prior to joining HealthCare Ventures, Mr. Onsi was at Genzyme Corporation, or Genzyme, where he served in roles as Vice President, Campath Product Operations and Portfolio Management, Oncology from 2005 to 2007 and as Vice President, Business Development from 2004 to 2005. Prior to Genzyme, he was Chief Financial Officer of Tolerx, Inc., a venture capital funded biotechnology company, from 2001 to 2004. Before joining Tolerx, Inc., he was in business development at LeukoSite, a publicly traded biopharmaceutical company that was acquired by Millennium Pharmaceuticals, Inc. He began his career as an attorney at Bingham Dana LLP. Mr. Onsi currently serves as a member of the board of directors of Vaxxas Pty Ltd., a privately-held biotechnology company. He received a Juris Doctor degree from the University of Michigan Law School and a B.S. in biological sciences from Cornell University.

J have worked as Chairman/Pres/CEO/Secy/Co-Founder at Genprex Inc. They work or have worked as MEMBER at STATE BAR OF TEXAS. J attended TAMU and University of Texas School of Law.

David is an entrepreneur and angel investor who has held operating roles at six startups and invested in 70 companies. He was most recently the Chief Executive Officer of Gradifi, which was acquired by E*TRADE. Previously, he was Entrepreneur-in-Residence at Harvard Business School and Director of the Babson Summer Venture Program.For more info, see www.davidchang.mePAST EXPERIENCEDavid has a successful track record in hands-on roles at both direct-to-consumer and enterprise companies, six of which were acquired or IPO’d. He previously led the PayPal Boston office and co-founded the Start Tank innovation space and the Where Angel Fund. Before WHERE’s acquisition by PayPal in April 2011, he held the role of VP of Product, which included strategy and corporate development.Earlier in his career, on the consumer side, David was Director of New Products at TripAdvisor where he launched new features to meet consumers’ needs. He was VP of Marketing and Co-founder of SnapMyLife where he led product and marketing efforts. On the enterprise side, David was Director of Product Marketing at m-Qube, a pioneer in the mobile content space. He was Senior Product Manager at edocs and was a VP of Technology at Goldman Sachs.As a leader in the entrepreneurship community, David holds several advisor/board memberships. He is on the board at MITX, an advisor at Harvard Ventures, Nanigans, CO Everywhere, OpenFrame, and Linkwell Health. He has made 70 angel investments in startups such as Crashlytics, clypd, Amino, Logz, Cuseum, CarePort Health, Dashfire, Mogul, Uncharted Play, through the Where Angel Fund and TBD Angels. David is a frequent speaker on the topics of startups, fundraising, and the Boston tech ecosystem, and he actively mentors students and founders. Awards include Boston Business Journal's Power 50: Most Influential Bostonians, BostInno’s 50 on Fire: Education Winner / Investment Winner / Tech Finalist, and Finalist for NEVY Angel of the Year.ADVISOR ROLESBoard Member at MITX, FeelterAdvisory Board Member at Inrupt, Harvard Ventures, Nanigans, CO Everywhere, Campseekers, SharalikeAdvisor & Mentor at MassChallengeMentor at TechStarsANGEL INVESTMENTS70 angel investments in startups such as Crashlytics, clypd, Amino, CarePort Health, WEVO, Cuseum, Dashfire, Mogul, Uncharted Play, xPeerient, and through the Where Angel Fund

Robert Ross is a Board Member at Obsidian Therapeutics, Board Member at SURFACE ONCOLOGY INC., and Chief Executive Officer at SURFACE ONCOLOGY INC. and is based in Brookline, Massachusetts. He has worked as Chief Medical Officer at SURFACE ONCOLOGY INC.. Robert studied at Columbia University in the City of New York between 1995 and 1999, Teachers College Columbia University, and Harvard University between 2005 and 2007.